Back to top

Analyst Blog

Infinity Pharmaceuticals Inc. (INFI - Snapshot Report) reported a loss of 57 cents per share in the first quarter of 2013 narrower than the Zacks Consensus Estimate of a loss of 67 cents, but wider than the year-ago loss of 40 cents. The narrower-than-expected loss was primarily due to lower operating expenses incurred by the company in the first quarter of 2013.

Infinity Pharma did not generate any revenue during first quarter of 2013; however, it had recorded $25.2 million as collaborative research and development revenue in the year-ago quarter.

Other Details

Infinity Pharma’s research and development (R&D) expenses decreased 29.1% to $20.3 million in the first quarter of 2013. The decrease was primarily due to the discontinuation of the company’s Hedgehog pathway development program. The company’s general and administrative (G&A) expenses increased 9.1% to $7.4 million.

Infinity Pharma is working on its pipeline. The company intends to present data on retaspimycin hydrochloride (HCl) from two studies in the second half of 2013. One is in combination with Sanofi’s (SNY - Analyst Report) Taxotere (docetaxel) and the other in combination with Novartis’ (NVS - Analyst Report) Afinitor (everolimus). Both the studies are evaluating retaspimycin HCl for the treatment of non-small cell lung cancer.

The company also has IPI-145 in its pipeline under its phosphoinositide-3-kinase (PI3K) program.  IPI-145 is being developed for several indications at various stages. The company is expecting several data read-outs and trial initiations under this program this year.

Infinity Pharma currently carries a Zacks Rank #3 (Hold). Other stocks such as Inovio Pharmaceuticals Inc. (INO - Snapshot Report), with a Zacks Rank #1 (Strong Buy), currently looks more attractive in the pharma space.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.00 +3.09%
SANCHEZ ENE… SN 34.18 +2.67%
THE PANTRY… PTRY 21.02 +2.09%
INTEL CP INTC 35.15 +1.88%
PIPER JAFFR… PJC 54.54 +1.70%